Search alternatives:
greater decrease » greater increase (Expand Search), greater increases (Expand Search), rate decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
c decrease » c decreased (Expand Search), _ decrease (Expand Search), rc decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
greater decrease » greater increase (Expand Search), greater increases (Expand Search), rate decreased (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
c decrease » c decreased (Expand Search), _ decrease (Expand Search), rc decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
21
-
22
-
23
cAMP production is decreased in FX fly.
Published 2013“…(a) RF-based cAMP measures in the fly head (Control n = 10, FX n = 3, FXR+ n = 6; FXR++ n = 6 sets of 20 heads) are comparable between groups in the absence of forskolin [F(3,21) = 1.96; p = 0.15], but not its presence [F(3,21) = 6.23;p = 0.003], since RF intensity in FX flies is larger than the others [t(21) = −4.10;p = 0.000]. …”
-
24
-
25
-
26
Activation of AKT, decrease in FOXO and activation of glycolytic genes in CERT heterozygous mice.
Published 2013“…Comparison of different FOXO in liver tissue of wild type (+/+) and CERT heterozygous (+/−) mice shows significant decrease in their transcript levels. (C). Comparison of glycolytic genes in skeletal muscle from wild type (+/+) and CERT heterozygous (+/−) mice shows greater than 5 fold increase in transcript levels of phosphoglycerate mutase and pyruvate kinase and 1.8 fold increase in hexokinase. …”
-
27
-
28
-
29
The novel <i>carboxylesterase 1</i> variant c.662A>G may decrease the bioactivation of oseltamivir in humans
Published 2017“…A novel <i>CES1</i> c.662A>G single nucleotide polymorphism (SNP) was predicted to decrease CES1 enzymatic activity in an <i>in silico</i> analysis. …”
-
30
-
31
-
32
-
33
-
34
-
35
-
36
-
37
-
38
-
39
-
40